TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33214446
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy alone (control)
Study: 32936427
Drug: TRZ30 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRZ30 (10 mg three times daily for 8 weeks)
Study: 32936427
Drug: TRZ60 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRZ60 (20 mg three times daily for 8 weeks)
Study: 34938354
Drug: Bisphosphonate drugs
Normalized name: Bisphosphonate drugs affecting bone structure and mineralization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate drugs
Study: 35432844
Drug: Insulin combined
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin combined with Traditional Chinese Medicine (TCM) prescription
Study: 35432844
Drug: Nursing intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing intervention based on control group (Insulin + TCM)
Study: 33168910
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (antibiotics)
Study: 35643873
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein yogurt (10 g protein/100 g)
Study: 35643873
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein yogurt (3.5 g protein/100 g)
Study: 34673449
Drug: Computer-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based therapy
Study: 34673449
Drug: Therapist-mediated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-mediated therapy
Study: 36592517
Drug: 0.1 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/L Schisandrin B
Study: 36592517
Drug: 0.5 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/L Schisandrin B
Study: 33772456
Drug: Pentoxiphylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxiphylline (PTX) and Vitamin E (VE) combination (PTVE group)
Study: 32615392
Drug: Probiotics (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (6 g/d for 6 months)
Study: 32615392
Drug: Synbiotics (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics (6 g/d for 6 months)
Study: 32615392
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 6 g/d for 6 months)
Study: 35645564
Drug: Congruence Couple
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Congruence Couple Therapy (CCT)
Study: 35645564
Drug: Treatment‐as‐Usual (TAU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment‐as‐Usual (TAU)
Study: 34985236
Drug: Sham manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham manual therapy technique (CG)
Study: 32641470
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 440 mg
Study: 33906234
Drug: ALB (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALB (400 mg) plus IVM (600 μg/kg) for 3 consecutive days
Study: 34872341
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis combined with EVT (combination-therapy group)
Study: 35226099
Drug: Low-dose rh
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rh insulin (400-μIU/mL milk)
Study: 35226099
Drug: High-dose rh
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rh insulin (2000-μIU/mL milk)
Study: 33750266
Drug: Probiotic acidophilus
Normalized name: Probiotic Acidophilus 1mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic acidophilus milk (100 g/day, 107 cfu/g)
Study: 33750266
Drug: Freshly prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freshly prepared 'dahi' (100 g/day, 107 cfu/g)
Study: 33750266
Drug: Thermal processed
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal processed buffalo milk (100 ml/day)
Study: 32683390
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel containing 0.2% chlorhexidine, 0.5% chitosan, 5% dexpanthenol, 0.15% allantoin, and 0.01% sodium saccharin
Study: 32007714
Drug: Stabilising chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilising chemotherapy
Study: 33260292
Drug: Strong parental
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strong parental support for breakfast as the main daily meal
Study: 36309950
Drug: Carbidopa doses
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbidopa doses with 200 mg entacapone
Study: 33450160
Drug: Laparoscopic adrenalectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic adrenalectomy (LA-g)
Study: 34093444
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment
Study: 34716902
Drug: RIST4721 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIST4721 300 mg once daily for 28 days
Study: 35768027
Drug: Treatment received
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment received by patients
Study: 32945860
Drug: Gamified ICTs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamified ICTs (42 daily and 2 weekly sessions)
Study: 32945860
Drug: Nongamified ICTs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nongamified ICTs (42 daily and 2 weekly sessions)
Study: 35355249
Drug: KHKi 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHKi 50 mg once daily
Study: 35355249
Drug: KHKi alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHKi alone (100–600 mg)
Study: 34428929
Drug: non-ACE/ARB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-ACE/ARB treatment
Study: 35199834
Drug: 1000 mg/d
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/d DHA (experimental group: EXP)
Study: 36185549
Drug: Upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 15 mg plus topical corticosteroids (TCS)
Study: 36185549
Drug: Upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 30 mg plus topical corticosteroids (TCS)
Study: 36185549
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus topical corticosteroids (TCS)
Study: 35411924
Drug: Synbiotic yogurt
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic yogurt (SYN) containing inulin (4 g) and Lactobacillus rhamnosus GG (>1 × 10^7 CFU/mL)
Study: 34127095
Drug: Cariprazine (3-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine (3-12 mg/d, 3-6 mg/d, or 6-12 mg/d for 3 weeks)
Study: 34766785
Drug: laboratory alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: laboratory alcohol self-administration
Study: 36343645
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 (10-360 mg once daily for 14 days)
Study: 36343645
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 187004 (≥40 mg once daily for 14 days)
Study: 32046452
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily + COC containing drospirenone for 21 days
Study: 35926795
Drug: Periarticular Injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular Injection (PAI)
Study: 33205362
Drug: Daridorexant 50
Normalized name: daridorexant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daridorexant 50 mg with ethanol
Study: 33205362
Drug: Daridorexant 50
Normalized name: daridorexant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daridorexant 50 mg alone
Study: 33747081
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (TCA)
Study: 32762161
Drug: gonadotrophin releasing
Normalized name: Gonadotrophin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: gonadotrophin releasing hormone analogue (GnRHa)
Study: 32338316
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron
Study: 33678106
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg at weeks 0, 4, 16, and 28
Study: 33678106
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg at week 4
Study: 33678106
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg at week 16
Study: 35943798
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg twice a day
Study: 37490202
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every 2 weeks
Study: 35167999
Drug: Prickly Pear
Normalized name: Prickly Pear Fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prickly Pear juice (250 mL; 45 mg betalain content; reduced fiber)
Study: 33038062
Drug: E6011 400/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 400/200 mg
Study: 33038062
Drug: E6011 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 100 mg (in subgroup with higher baseline CD16+ monocytes)
Study: 33038062
Drug: E6011 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 200 mg (in subgroup with higher baseline CD16+ monocytes)
Study: 33038062
Drug: E6011 400/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 400/200 mg (in subgroup with higher baseline CD16+ monocytes)
Study: 34134579
Drug: Adalimumab injecta
Normalized name: adalimumab Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab injecta (40 mg)
Study: 34134579
Drug: Humira® (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humira® (40 mg)
Study: 35057579
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral glucose tolerance test (OGTT))
Study: 34758210
Drug: Peer-delivered group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-delivered group cognitive-behavioral therapy (CBT) for postpartum depression (PPD)
Study: 32350679
Drug: Breast Conservation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast Conservation Therapy (BCT)
Study: 34633116
Drug: Romosozumab 210
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 210 mg sc every month for 2 months
Study: 35599000
Drug: Prasugrel (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (3.75 mg/day)
Study: 36286886
Drug: Bismuth-based quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based quadruple therapy with Bifiform (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bismuth tripotassium dicitrate 240 mg, Bifiform 2 capsules 2 times a day for 14 days)
Study: 36286886
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group therapy (same as main group but without Bifiform)
Study: 33277803
Drug: Platelet count
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet count (PLT) > 105 × 10^9/L
Study: 34559394
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone (10 mg)
Study: 34253806
Drug: Cold bubbled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold bubbled humidified oxygen therapy (OX + HUMID)
Study: 34253806
Drug: Dry oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry oxygen therapy (OX + DRY)
Study: 35576384
Drug: Antibiotics (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (intravenous ertapenem followed by oral levofloxacin and metronidazole)
Study: 33752446
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) (n = 37)
Study: 33781638
Drug: Closed-incision negative-pressure
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-incision negative-pressure therapy (ciNPT)
Study: 34474584
Drug: Drug-Eluting Balloons
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Balloons (DEB)
Study: 33509845
Drug: Antibiotic-loaded bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-loaded bone cement (ALBC)
Study: 35932699
Drug: Betta fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betta fish therapy (kept at home for 2 months)
Study: 33395924
Drug: Salbutamol (SAL)
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol (SAL) 400 µg
Study: 32043907
Drug: Inotersen 300
Normalized name: INOTERSEN
DrugBank: Inotersen (DB14713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotersen 300 mg/week
Study: 33851246
Drug: Outpatient physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient physical therapy (superficial heater + deep heater + transcutaneous electrical nerve stimulation) for 2 weeks and spa therapy
Study: 33851246
Drug: Inpatient physical
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient physical therapy (superficial heater + deep heater + transcutaneous electrical nerve stimulation) for 2 weeks and spa therapy
Study: 32234653
Drug: High-protein formula
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein formula (2.1 g protein/100 kcal)
Study: 32740903
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium valproate (iVPA)
Study: 32125665
Drug: Finerenone 20
Normalized name: finerenone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 20 mg orally
Study: 33583360
Drug: Cecolin® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cecolin® vaccine (high ISAR score)
Study: 32562682
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management plus interventional therapy
Study: 34609621
Drug: PROT (advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROT (advice to increase protein intake to ≥ 1.2 g/kg aBW/d)
Study: 33509352
Drug: Short taper
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short taper of steroids over 36 days after remission
Study: 32326966
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (HSP, HSP+, Casein)
Study: 37366571
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (AAD)
Study: 33653815
Drug: Antidiabetic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic drug users (including insulin and metformin)
Study: 33653815
Drug: Antidiabetic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic drug users
Study: 34914216
Drug: Tadalafil combined
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil combined with behavioral therapy and psychological counseling
Study: 32252716
Drug: Guideline Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline Daily Amounts (GDA)
Study: 34847900
Drug: Counseling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling with hope therapy (8 sessions of 45 minutes, twice a week)
Study: 36126255
Drug: Morphine-Midazolam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-Midazolam (5 mg each)
Study: 35583116
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of antibiotics
Study: 33184979
Drug: oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral semaglutide (4-week dose escalation from 3 to 7 to 14 mg)
Study: 38753273
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM)
Study: 33023067
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d algal DHA
Study: 35857132
Drug: Multi-strain probiotic
Normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-strain probiotic (Lactobacillus acidophilus UBLA‐34, L. rhamnosus UBLR‐58, L. reuteri UBLRu‐87 (2 billion CFU each), L. plantarum UBLP‐40, L. casei UBLC‐42, L. fermentum UBLF‐31, Bifidobacterium bifidum UBBB‐55 (1 billion CFU each) and fructo‐oligosaccharides (100 mg)) along with dietary and lifestyle modifications
Study: 32490570
Drug: Tumor debulking
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor debulking followed by chemotherapy
Study: 32490570
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with chemotherapy
Study: 34951464
Drug: Dextroamphetamine (oral;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (oral; 0.43 mg/kg)
Study: 32382551
Drug: anti-VEGF treatment
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-VEGF treatment (ProReNata approach)
Study: 36404400
Drug: Mirabegron (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (50 mg daily, titrated to 200 mg daily, n=39)
Study: 35620165
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (twice or three times per week intravenous)
Study: 35620165
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (once per week intravenous)
Study: 34940699
Drug: Whole biomass
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole biomass of Phaeodactylum tricornutum (PT) at 5.3 g/day
Study: 34940699
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) containing equal amounts of EPA and DHA (300 mg/day)
Study: 35795994
Drug: Prehabilitation during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehabilitation during neoadjuvant therapy
Study: 35795994
Drug: Loss of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loss of VAT during neoadjuvant therapy
Study: 34181148
Drug: Oxycodone-paracetamol (OPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone-paracetamol (OPT group)
Study: 32154123
Drug: Paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone extended-release (oral, flexibly dosed, 1.5‐12 mg/day)
Study: 32993832
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of a package of noncommunicable disease interventions including cardiovascular risk scoring, hypertension management, and statin treatment.
Study: 34028130
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy before amniocentesis (group 1)
Study: 34990968
Drug: Adjuvant clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant clonidine (0.2 mg/d to a maximum of 0.6 mg/d)
Study: 33561199
Drug: Multi-factor experiment
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-factor experiment with a combination of surface area‐to‐volume ratio, oil density, and oil thickness
Study: 33561199
Drug: Repeatability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeatability of identical treatments
Study: 32171749
Drug: Step-by-step video
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-by-step video demonstration (1 to 2 hours preparation)
Study: 35109502
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (monthly recreational session during the same period)
Study: 34969609
Drug: Qualified practitioner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualified practitioner Johrei treatment
Study: 34510189
Drug: 67 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 67 g/d of soy nuts providing ~25.5 g protein and 174 mg isoflavones
Study: 34510189
Drug: 67 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 67 g/d of soy nuts
Study: 35709019
Drug: Restrictive intravenous
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive intravenous fluid therapy
Study: 35709019
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous fluid therapy
Study: 33196584
Drug: Self-administered daily
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered daily low-intensity pulsed ultrasound
Study: 33439978
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe as ferrous fumarate with 0 mg folic acid
Study: 33439978
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe as ferrous fumarate with 0.4 mg folic acid